Skip to main content
NewslettersWatchlist

Alimera Sciences Inc(ALIM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Alimera Sciences Inc

6310 TOWN SQUARE SUITE 400
ALPHARETTA GA 30005 USA
P: 678-990-5740
F: 678-990-5744
http://www.alimerasciences.com

Sectors & Indices

Sector
Industry
Employees

Profile

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

Key Executives

NameTitle
Richard S. EiswirthCEO/Director/President
Elliot MaltzCFO/Chief Accounting Officer

More from The Globe

The close: Major indexes fall after wage data; cannabis shares surge on U.S. regulatory move
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.
The close: Stocks higher as investors focus on Fed moves
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26.
The close: Major North American indexes rise as megacap tech stocks rally
A trader works on the floor at the New York Stock Exchange (NYSE) on April 25.
Why this money manager is venturing back into emerging markets and adding more U.S. tech
Illustration of Andrew Pyle for The Mover. Nov. 5, 2022. Illustration by Joel Kimmel
How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy
Former President Donald Trump sits in Manhattan Criminal Court in New York, Thursday, April 25.
Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders
Dye & Durham Ltd. says it has launched a strategic review of its non-core assets in an effort to reduce its debt. The logo for Dye & Durham Ltd. is shown in this undated handout photo. THE CANADIAN PRESS/HO
The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market
Traders work on the floor of the New York Stock Exchange shortly after the opening bell, Wednesday, April 24.
Fiera Capital’s largest shareholder looks to sell stake in company
Jean-Guy Desjardins, global CEO and founder of Fire Capital posses for a portrait at Fiera Capital, in Montreal on Monday, January 8, 2024. Evan Buhler/The Globe and Mail�

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.